Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of ...

The Therapeutic Goods Administration (TGA) has made the decision not to register lecanemab (LEQEMBI) for the treatment of ...

In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

Lilly believes Kisunla can generate blockbuster sales. Kisunla is only the second drug on the market to treat Alzheimer's ...

New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...

Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.

About 40% of hormone-positive breast cancers in postmenopausal women might be linked to excess body fat, researchers reported ...